Clinical trials: Overactive Bladder (OAB)
Treatment of Patients Suffering From Overactive Bladder (OAB)
BlueWind RENOVA iStim™ System for the Treatment of OAB
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with…
- Trial name
- OASIS (NCT03596671)
- Testing
- RENOVA iStim™ System
- Where
- 23 sites in United States, Belgium and 2 more
- Volunteers
- 282 people
- Sponsor
- BlueWind Medical
Overactive Bladder (OAB)
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
- Trial name
- PILLAR (NCT02216214)
- Testing
- Mirabegron
- Where
- 120 sites in United States, Canada
- Volunteers
- 888 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Overactive Bladder (OAB), Pharmacokinetics of Mirabegron
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and…
- Trial name
- Dolphin (NCT04641975)
- Testing
- Mirabegron
- Where
- 15 sites in Belgium, France and 8 more
- Volunteers
- 26 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder (OAB)
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
The objective of the study was to evaluate the safety and efficacy of add-on therapy with anticholinergics in patients with OAB on mirabegron.
- Trial name
- NCT02294396
- Testing
- Mirabegron tablet, Solifenacin tablet, Propiverine tablet
- Where
- 7 sites in Japan
- Volunteers
- 649 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder (OAB)
Drug Use Investigation for Toviaz
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
- Trial name
- NCT01936870
- Testing
- Fesoterodine (Toviaz)
- Volunteers
- 2,521 people
- Sponsor
- Pfizer
Overactive Bladder (OAB)
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency…
- Trial name
- PREFER (NCT02138747)
- Testing
- Mirabegron, Tolterodine ER
- Where
- 30 sites in United States, Canada
- Volunteers
- 376 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
- Trial name
- NCT01286454
- Testing
- fesoterodine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer